We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
신규 편입 · 포트폴리오 비중 0.02%
신규 편입 · 포트폴리오 비중 0.00%
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $44.57 · 7 analysts
Stored first · Google News · Yahoo Finance (English)
FMR LLC Significantly Reduces Stake in Centessa Pharmaceuticals PLC - GuruFocus
FMR LLC Significantly Reduces Stake in Centessa Pharmaceuticals PLC GuruFocus
FMR LLC reports 1,800 Centessa shares (NASDAQ: CNTA) - Stock Titan
FMR LLC reports 1,800 Centessa shares (NASDAQ: CNTA) Stock Titan
Precision Trading with Centessa Pharmaceuticals Plc (CNTA) Risk Zones - Stock Traders Daily
Precision Trading with Centessa Pharmaceuticals Plc (CNTA) Risk Zones Stock Traders Daily
[15-12G] Centessa Pharmaceuticals plc SEC Filing - Stock Titan
[15-12G] Centessa Pharmaceuticals plc SEC Filing Stock Titan
Farallon Capital Management LLC Sells Out of Centessa Pharmaceuticals PLC - GuruFocus
Farallon Capital Management LLC Sells Out of Centessa Pharmaceuticals PLC GuruFocus
Enterprise value to revenue forward of Centessa Pharmaceuticals PLC ADR – MUN:260 - TradingView
Enterprise value to revenue forward of Centessa Pharmaceuticals PLC ADR – MUN:260 TradingView
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 05. 14. | After market close (AMC) | $-0.4 | — | — | $0 | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $-0.2 | — | — | $15M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-1.15 | — | — | $0 | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-0.78 | — | — | $0 | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 04. 21. | Wells Fargo | — | Downgrade | Overweight → Equal-Weight | — | Wells Fargo: Overweight → Equal-Weight |
| 2026. 04. 02. | Guggenheim | — | Downgrade | Buy → Neutral | — | Guggenheim: Buy → Neutral |
| 2026. 04. 02. | Leerink Partners | — | Downgrade | Outperform → Market Perform | — | Leerink Partners: Outperform → Market Perform |
| 2026. 04. 01. | Wolfe Research | — | Downgrade | Outperform → Peer Perform | — | Wolfe Research: Outperform → Peer Perform |
| 2026. 03. 31. | Needham | — | Downgrade | Buy → Hold | — | Needham: Buy → Hold |
| 2026. 02. 24. | Wolfe Research | — | Initiate coverage | — → Outperform | — | Wolfe Research: Outperform |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 307,355 | $12.21M | 0.02% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 59,844 | $2.38M | 0.00% | — | New position |
| 3 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 57,444 | $1.44M | 0.00% | — | New position |